UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

(Rule 14a-101)

 

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

 

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No. )

 

Filed by the Registrant [x]

Filed by a Party other than the Registrant [ ]

Check the appropriate box:

[ ] Preliminary Proxy Statement

[ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

[ ] Definitive Proxy Statement

[x] Definitive Additional Materials

[ ] Soliciting Material Pursuant to Rule 14a-12

 

ENDRA LIFE SCIENCES INC.

(Name of Registrant as Specified in its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

[x]    No fee required.

 

[ ]    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)Title of each class of securities to which transaction applies: N/A

 

(2)Aggregate number of securities to which transaction applies: N/A

 

(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): N/A

 

(4)Proposed maximum aggregate value of transaction: N/A

 

(5) Total fee paid: N/A

 

[ ]Fee paid previously with preliminary materials.

 

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)           Amount Previously Paid: N/A

 

(2)           Form, Schedule or Registration Statement No.: N/A

 

(3)           Filing Party: N/A

 

(4)           Date Filed: N/A

 

 

 

ENDRA Life Sciences Inc.				CONTROL ID:
				REQUEST ID:
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS
		DATE:	TUESDAY, JUNE 8, 2021
		TIME:	10:00 a.m. EASTERN TIME
		LOCATION:	https://agm.issuerdirect.com/ndra
HOW TO REQUEST PAPER COPIES OF OUR MATERIALS
PHONE: Call toll free 1-866-752-8683		FAX: Send this card to 202-521-3464	INTERNET:  https://www.iproxydirect.com/NDRA  and follow the on-screen instructions.		EMAIL: proxy@iproxydirect.com Include your Control ID in your email.
This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/NDRA
If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before May 25, 2021.
you may enter your voting instructions at: https://www.iproxydirect.com/NDRA   until 11:59 pm eastern time June 7, 2021.
	The purposes of this meeting are as follows:
	1. to elect five (5) nominees to the Board of Directors as nominated by the Board of Directors: Francois Michelon, Louis J. Basenese, Anthony DiGiandomenico, Michael Harsh and Alexander Tokman.   2. To ratify the appointment of RBSM LLP as the Company’s independent registered public accounting firm for 2021.   3. To transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.
Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.   The board of directors has fixed the close of business on April 22, 2021 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our common stock, par value $0.0001 per share, and series a convertible preferred stock, par value $0.0001 per share, they held on that date at the meeting or any postponement or adjournment of the meeting.
The Board of Directors recommends that you vote ‘for’ all proposals above.
Please note - This is not a Proxy Card - you cannot vote by returning this card.

 

 

 

ENDRA LIFE SCIENCES INC.

SHAREHOLDER SERVICES

1 Glenwood Avenue Suite 1001

Raleigh NC 27603

 

 

 

 

 

TIME SENSITIVE SHAREHOLDER INFORMATION ENCLOSED

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMPORTANT SHAREHOLDER INFORMATION

 

YOUR VOTE IS IMPORTANT